NEKTAR THERAPEUTICS
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $10.10M | $-1.23 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | $21.80M | $-1.78 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $11.80M | $-1.87 | $-1.85 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $11.20M | $-2.95 | $-2.78 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $10.50M | $-0.24 | $-0.22 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 12, 2025 | After market close | $29.20M | $0.03 | $-0.15 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $24.10M | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | $23.50M | $-0.25 | $-0.19 |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 4, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 7, 2023 | After market close | – | – | – |
Press releases
Announcements Nektar Therapeutics filed with the SEC
PRESS RELEASE ISSUED BY NEKTAR THERAPEUTICS ON OCTOBER 1, 2026, FURNISHED HEREWITH
Regulation FD disclosure · EX-99.1 to Form 8-K
NEKTAR THERAPEUTICS PRESENTATION, FURNISHED HEREWITH
Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2026 RESULTS."
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2026 RESULTS."
Results of operations · EX-99.1 to Form 8-K
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
16-Week Blinded Treatment Extension of REZOLVE-AA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Extension Treatment Period Rezpegaldesleukin in Patients with Severe-to-Very-Severe Alopecia Areata April 20, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 2b REZOLVE-AD: Topline Results
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Treatment Period Rezpegaldesleukin in Patients with Severe-to-Very-Severe Alopecia Areata December 16, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE TITLED "NEW DATA FROM REZOLVE-AD STUDY OF REZPEGALDESLEUKIN PRESENTED IN LATE-BREAKING ORAL ABSTRACT PRESENTATION AT ACAAI 2025 ANNUAL SCIENTIFIC MEETING."
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
SLIDES TITLED "EFFICACY AND SAFETY OF REZPEGALDESLEUKIN, A SELECTIVE REGULATORY T-CELL-INDUCING INTERLEUKIN-2 CONJUGATE, IN THE TREATMENT OF ATOPIC DERMATITIS: FINAL RESULTS FROM THE 16-WEEK INDUCTION OF A RANDOMIZED PHASE 2B STUDY (REZOLVE AD)"
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR PRESENTS NEW DATA FROM REZOLVE-AD PHASE 2B STUDY FOR REZPEGALDESLEUKIN IN LATE-BREAKER ORAL PRESENTATION AT EADV 2025"
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS"
Results of operations · EX-99.1 to Form 8-K
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY NEKTAR THERAPEUTICS ON JUNE 24, 2025, FURNISHED HEREWITH
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NEKTAR THERAPEUTICS CORPORATE PRESENTATION, FURNISHED HEREWITH
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
FINAL CONFIDENTIAL PRESS RELEASE FOR ISSUANCE
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS"
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS"
Material agreement · Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTARTHERAPEUTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS."
Results of operations · EX-99.1 to Form 8-K
SLIDES TITLED "REZPEGALDESLEUKIN (REZPEG) CORRECTED PHASE 1B DATASET FOR STUDIES OF REZPEG IN ATOPIC DERMATITIS AND PSORIASIS"
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR ANNOUNCES PROMISING NEW AND CORRECTED REZPEGALDESLEUKIN EFFICACY DATA WHICH WERE PREVIOUSLY REPORTED IN 2022 AND INCORRECTLY CALCULATED BY FORMER COLLABORATOR ELI LILLY & COMPANY"
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS"
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS ANNOUNCES IT WILL REGAIN FULL RIGHTS TO REZPEGALDESLEUKIN (REZPEG, NKTR-358), A NOVEL, FIRST-IN-CLASS SELECTIVE REGULATORY T-CELL (TREG) THERAPY IN CLINICAL DEVELOPMENT"
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS ANNOUNCES STRATEGIC REPRIORITIZATION AND COST RESTRUCTURING PLAN"
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE TITLED NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
PRESENTATION TITLED "PHASE 2 ISLAND STUDY OF REZPEG IN SLE"
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE TITLED "NEKTAR THERAPEUTICS ANNOUNCES PHASE 2 TOPLINE DATA FOR REZPEGALDESLEUKIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS"
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K